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FIGURE 1.  Panels A, C, and E show 
one case of epithelioid mesothelioma 
with MET gene amplification. A, hema-
toxylin and eosin–stained sections 
(magnification 10×); C, interphase 
fluorescence in situ hybridization 
(FISH) analysis showing amplification 
of MET (white arrows indicate spots of 
MET red* signal points) with a MET/
CEP7 ratio of 4.0 (approximately 
eight red signals vs. two green signals; 
magnification 100×); E, immunohisto-
chemistry (IHC) staining with anti-c-
MET antibody showing overexpression 
on cytoplasm and membrane of MET 
protein (magnification 40×). Panels B, 
D and F show one case of epithelioid 
mesothelioma with wild-type gene 
status and negative expression of MET 
protein. B, hematoxylin and eosin 10×; 
D, FISH for MET gene 100×; F: IHC for 
MET protein 40×. MET gene amplifica-
tion was investigated by FISH using the 
probe MET/CEP7 cocktail (Vysis MET 
Spectrum Red FISH Probe Kit reagent/
Vysis CEP 7 [D7Z1] SpectrumGreen 
Probe, both reagents from Abbott 
Molecular, Des Plaines, IL). IHC stain-
ing of MET was performed by Anti-
c-Met Antibody IHC-plus LS-B2812 
(LSBio, Seattle, WA).
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To the Editor:
In a subset of non–small-cell 
lung carcinomas, rearrangement of 
the EML4 and ALK genes creates the 
oncogenic fusion gene EML4–ALK, 
which encodes a chimeric protein with 
constitutive kinase activity that is most 
often seen in adenocarcinoma. Here, 
we present a extremely rare case of 
EML4–ALK-positive atypical cartinoid 
in which crizotinib was administered.
CASE PRESENTATION
A 54-year-old woman who 
was a light ex-smoker was referred 
to our hospital for further evalua-
tion of an abnormal chest shadow and 
severe headache. Chest radiography 
and computed tomography revealed a 
solitary nodule, 20 mm in diameter, in 
the right middle lobe (Fig. 1A and B). 
Contrast-enhanced magnetic resonance 
imaging of the brain showed multiple 
skull metastases and extensive intra-
cranial invasion with severe cerebral 
edema. Fluorine 18-labeled fluorode-
oxyglucose-positron emission tomog-
raphy–computed tomography revealed 
abnormal fluorodeoxyglucose uptake in 
the lesion described above, and multiple 
bone metastases (Fig. 1C). Laboratory 
examinations revealed abnormally ele-
vated levels of neuron-specific enolase 
(72.6 ng/ml) and progastrin-releasing 
peptide (6446.0 ng/ml). There were no 
abnormalities in any other laboratory 
variables, including carcinoembryonic 
antigen and cytokeratin 19 fragment.
We performed fiberoptic bron-
choscopy to evaluate the 20-mm 
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solitary nodule. The histopathological 
diagnosis was an atypical carcinoid 
consisting of sheets of cuboidal cells 
with round nuclei of various sizes and 
eosinophilic granular cytoplasm. The 
result of immunoreactivity to chromo-
granin A, synaptophysin, and CD56 
was positive (Fig. 2). Molecular analy-
sis of exons 18, 19, 20, and 21 of the 
epidermal growth factor receptor gene 
revealed no mutations. In contrast, 
both fluorescence in situ hybridization 
analysis with break-apart probes for the 
ALK gene and sensitive ALK immuno-
histochemistry revealed the presence of 
ALK rearrangement. Moreover, subse-
quent reverse transcriptase-polymerase 
chain reaction analysis confirmed the 
presence of transcripts for variant 3a/b 
of the EML4–ALK fusion gene (Fig. 3).
A B C D
FIGURE 1. A and B, Computed 
tomography (CT) scan of thorax 
before initiation of crizotinib; C, 
positron emission tomography–CT 
scan before initiation of crizotinib; 
D, CT scan of thorax after 18 days of 
treatment with crizotinib.
FIGURE 2.  Histopathological image 
of the transbronchial biopsy speci-
men. The result of immunoreactivity 
was positive for chromogranin A, 
synaptophysin, and CD56.
After identification of the EML4–
ALK fusion gene and because the 
patient had a performance state of 3, 
crizotinib was administered orally at a 
dose of 250 mg daily. The lung tumors 
remained stable during treatment; 
however, 5 weeks later, disorientation 
developed, leading to marked degenera-
tion of the patient’s performance status. 
Crizotinib was then withdrawn.
DISCUSSION
We have described what we 
believe is the first reported case of 
atypical carcinoid in which the patient 
harbored variant 3a/b of the EML4-ALK 
fusion gene. To the best of our knowl-
edge, there have been four previous 
reports describing EML4–ALK-positive 
neuroendocrine lung tumors (small-cell 
carcinoma1,2 and large-cell neuroendo-
crine carcinoma3). Moreover, our patient 
is the second to receive crizotinib among 
the four reported cases.
Because Omachi et al3 previously 
reported that a case of large-cell neuro-
endocrine carcinoma did not respond to 
crizotinib therapy, we repeated reverse 
transcriptase-polymerase chain reaction 
to examine whether the tumor harbored 
resistance mutations such as L1152R, 
C1156Y, F1174L, L1196M, G1202R, 
S1206Y, and G1269A. However, none 
of these mutations were detected.
The frequency and clinical sig-
nificance of the fusion gene in neu-
roendocrine carcinoma have yet to 
be determined. It is hoped that future 
studies will elucidate the characteris-
tics of patients with neuroendocrine 
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FIGURE 3. EML4–ALK fusion gene 
in all four examinations (immuno-
histochemistry/fluorescence in situ 
hybridization/reverse transcriptase-
polymerase chain reaction/next 
generation sequencer).
carcinoma harboring the EML4–ALK 
rearrangement.
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To the Editor:
Malignant granular cell tumors 
(GCTs) are extremely rare. We read that 
De Luca et al1 reported a giant malignant 
GCT of posterior mediastinum. In this 
letter, we would like to share our experi-
ence of a case with malignant pulmonary 
GCT and explore the underlying mecha-
nisms by next generation sequencing.
A 63-year-old woman presented 
with chronic cough for several months. 
An enhanced chest computed tomogra-
phy indicated a large solitary mass in the 
lower lobe of left lung, approximately 
14 × 10 × 9 cm in size (Fig. 1). Physical 
examination, laboratory evaluation, and 
other radiological tests revealed no sig-
nificant abnormalities, with the excep-
tion of high expression of NSE (67.41 
μg/liter, range, 0–16.3 μg/liter). A bron-
choscopic biopsy was performed from 
the basal stem of left lower lobe, and the 
diagnosis of GCT was considered given 
that the immunohistochemistry staining 
of S-100 (+), Vimentin (+), and HMB45 
(−). Because GCTs are not sensitive 
to chemotherapy or radiotherapy,2–4 a 
complete left pneumonectomy together 
with systemic lymphadenectomy was 
therefore performed. Pleural metas-
tasis was found during the operation, 
and therefore, GCT of this patient was 
malignant. The diagnosis of pulmonary 
GCT was identified again by postop-
erative immunohistochemistry staining 
(Fig. 2). A gene mutation profiling was 
performed by next generation sequenc-
ing (OncoScreen TM 295 genes, 
Burning Rock Dx, Guangzhou, China; 
Supplemental Table, Supplemental 
Digital Content, http://links.lww.com/
JTO/A862). The results detected seven 
mutations on five genes. No copy number 
variation or fusion/translocation events 
